Total Payments
$7,058
2024 Payments
$1,136
Companies
36
Transactions
504
Medicare Patients
1,476
Medicare Billing
$339,142
Payment Breakdown by Category
Food & Beverage$6,950 (98.5%)
Education$108.52 (1.5%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,950 | 501 | 98.5% |
| Education | $108.52 | 3 | 1.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,161 | 61 | $0 (2024) |
| ViiV Healthcare Company | $686.73 | 30 | $0 (2024) |
| Insmed, Inc. | $647.92 | 18 | $0 (2023) |
| Melinta Therapeutics, LLC | $631.77 | 23 | $0 (2024) |
| ABBVIE INC. | $564.33 | 193 | $0 (2024) |
| Gilead Sciences, Inc. | $469.46 | 20 | $0 (2024) |
| Amgen Inc. | $315.27 | 4 | $0 (2019) |
| Allergan, Inc. | $281.32 | 58 | $0 (2020) |
| Astellas Pharma US Inc | $259.57 | 6 | $0 (2024) |
| Shionogi Inc | $215.27 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,136 | 102 | Shionogi Inc ($194.21) |
| 2023 | $1,133 | 97 | Insmed, Inc. ($186.16) |
| 2022 | $695.69 | 86 | ABBVIE INC. ($195.48) |
| 2021 | $397.07 | 20 | ViiV Healthcare Company ($164.82) |
| 2020 | $438.06 | 23 | Insmed, Inc. ($177.06) |
| 2019 | $1,326 | 91 | Merck Sharp & Dohme Corporation ($258.45) |
| 2018 | $1,098 | 39 | Merck Sharp & Dohme Corporation ($288.12) |
| 2017 | $834.15 | 46 | Amgen Inc. ($118.29) |
All Payment Transactions
504 individual payment records from CMS Open Payments — Page 19 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/27/2018 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $12.15 | General |
| 03/23/2018 | ViiV Healthcare Company | JULUCA (Drug), TRIUMEQ | Food and Beverage | In-kind items and services | $16.94 | General |
| Category: HIV | ||||||
| 03/20/2018 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug), SIVEXTRO | Food and Beverage | In-kind items and services | $16.80 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/01/2018 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $85.71 | General |
| Category: Cardiology | ||||||
| 02/15/2018 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $68.00 | General |
| Category: Cardiology | ||||||
| 02/14/2018 | ViiV Healthcare Company | JULUCA (Drug), TRIUMEQ | Food and Beverage | In-kind items and services | $15.14 | General |
| Category: HIV | ||||||
| 02/13/2018 | Merck Sharp & Dohme Corporation | ISENTRESS (Drug) | Food and Beverage | In-kind items and services | $13.51 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/08/2018 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $11.13 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/14/2017 | Gilead Sciences Inc | — | Food and Beverage | In-kind items and services | $16.82 | General |
| 11/13/2017 | AbbVie, Inc. | Mavyret (Drug) | Food and Beverage | In-kind items and services | $12.30 | General |
| Category: Virology | ||||||
| 10/27/2017 | Gilead Sciences Inc | — | Food and Beverage | In-kind items and services | $11.38 | General |
| 10/24/2017 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $12.46 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/18/2017 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug), SIVEXTRO | Food and Beverage | In-kind items and services | $17.16 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/16/2017 | The Medicines Company | MINOCIN IV (Drug), ORBACTIV | Food and Beverage | In-kind items and services | $15.38 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/06/2017 | Gilead Sciences Inc | — | Food and Beverage | In-kind items and services | $11.81 | General |
| 09/14/2017 | The Medicines Company | MINOCIN IV (Drug), ORBACTIV | Food and Beverage | In-kind items and services | $6.53 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/07/2017 | CSL Behring | Privigen (Biological) | Food and Beverage | In-kind items and services | $13.41 | General |
| Category: Immunoglobulins | ||||||
| 09/05/2017 | Merck Sharp & Dohme Corporation | ISENTRESS (Drug) | Food and Beverage | In-kind items and services | $13.39 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 08/18/2017 | ViiV Healthcare Company | TRIUMEQ (Drug), TIVICAY | Food and Beverage | In-kind items and services | $13.79 | General |
| Category: HIV | ||||||
| 08/10/2017 | Organogenesis Inc. | Apligraf (Device), Dermagraft | Food and Beverage | In-kind items and services | $88.19 | General |
| Category: wound | ||||||
| 07/24/2017 | Oxford Immunotec Inc. | TSPOT TB TEST (Device) | Food and Beverage | In-kind items and services | $13.02 | General |
| Category: Diagnostic Test | ||||||
| 07/21/2017 | Gilead Sciences Inc | — | Food and Beverage | In-kind items and services | $12.31 | General |
| 07/12/2017 | Seqirus USA Inc | RAPIVAB (Biological) | Food and Beverage | In-kind items and services | $10.92 | General |
| Category: Vaccine | ||||||
| 07/11/2017 | The Medicines Company | MINOCIN IV (Drug), ORBACTIV | Food and Beverage | In-kind items and services | $11.48 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 06/28/2017 | ViiV Healthcare Company | TRIUMEQ (Drug), TIVICAY | Food and Beverage | In-kind items and services | $12.14 | General |
| Category: HIV | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 418 | 893 | $167,538 | $62,263 |
| 2022 | 4 | 204 | 453 | $79,548 | $29,939 |
| 2021 | 13 | 392 | 4,431 | $387,651 | $139,916 |
| 2020 | 14 | 462 | 6,172 | $552,058 | $107,025 |
Total Patients
1,476
Total Services
11,949
Medicare Billing
$339,142
Procedure Codes
36
All Medicare Procedures & Services
36 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 103 | 394 | $78,800 | $34,097 | 43.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 77 | 198 | $39,476 | $11,361 | 28.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 69 | 72 | $27,720 | $9,066 | 32.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 74 | 77 | $20,174 | $7,260 | 36.0% |
| 96127 | Assessment of emotional or behavioral problems | Office | 2023 | 95 | 152 | $1,368 | $478.91 | 35.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 94 | 294 | $40,572 | $15,191 | 37.4% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 73 | 81 | $21,222 | $8,014 | 37.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 25 | 66 | $13,134 | $4,985 | 38.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 12 | 12 | $4,620 | $1,748 | 37.8% |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | Office | 2021 | 12 | 2,630 | $198,000 | $88,073 | 44.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 113 | 274 | $32,628 | $14,621 | 44.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2021 | 23 | 243 | $67,742 | $10,457 | 15.4% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 75 | 76 | $17,622 | $7,672 | 43.5% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 22 | 67 | $20,100 | $6,699 | 33.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 25 | 61 | $12,076 | $4,677 | 38.7% |
| 96415 | Infusion of chemotherapy into a vein | Office | 2021 | 22 | 115 | $7,475 | $2,477 | 33.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 14 | 14 | $4,791 | $2,004 | 41.8% |
| 96360 | Hydration infusion into a vein 31 minutes to 1 hour | Office | 2021 | 23 | 76 | $9,750 | $1,818 | 18.6% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 12 | 12 | $2,242 | $843.74 | 37.6% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2021 | 12 | 736 | $14,720 | $298.57 | 2.0% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2021 | 16 | 54 | $432.00 | $237.34 | 54.9% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2021 | 23 | 73 | $73.00 | $37.71 | 51.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2020 | 53 | 715 | $200,200 | $34,508 | 17.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 102 | 293 | $32,230 | $16,029 | 49.7% |
| 96374 | Injection of drug or substance into a vein for therapy, diagnosis, or prevention | Office | 2020 | 25 | 449 | $125,720 | $12,166 | 9.7% |
About Dr. Jack Austin, MD
Dr. Jack Austin, MD is a Infectious Disease healthcare provider based in Augusta, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1972612190.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jack Austin, MD has received a total of $7,058 in payments from pharmaceutical and medical device companies, with $1,136 received in 2024. These payments were reported across 504 transactions from 36 companies. The most common payment nature is "Food and Beverage" ($6,950).
As a Medicare-enrolled provider, Austin has provided services to 1,476 Medicare beneficiaries, totaling 11,949 services with total Medicare billing of $339,142. Data is available for 4 years (2020–2023), covering 36 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Augusta, GA
- Active Since 08/30/2006
- Last Updated 02/21/2025
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1972612190
Products in Payments
- AVYCAZ (Drug) $581.25
- Arikayce (Drug) $546.54
- Repatha (Biological) $315.27
- PIFELTRO (Drug) $279.69
- Baxdela (Drug) $277.73
- Rezzayo (Drug) $254.24
- ISENTRESS (Drug) $229.70
- CABENUVA (Biological) $221.43
- ZERBAXA (Drug) $221.16
- PANZYGA (Biological) $218.41
- Fetroja (Drug) $215.27
- Biktarvy (Drug) $193.06
- DOVATO (Drug) $170.73
- NUZYRA (Drug) $170.35
- DIFICID (Drug) $170.14
- Cresemba (Drug) $155.24
- TRIUMEQ (Drug) $143.39
- Xerava (Drug) $135.10
- Apligraf (Biological) $125.88
- OCTAGAM IMMUNE GLOBULIN (HUMAN) (Drug) $117.63
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Augusta
Cheryl Newman, Md, MD
Infectious Disease — Payments: $150,138
Infectious Disease $150,138
John Rissing, Md, MD
Infectious Disease — Payments: $43,837
Infectious Disease $43,837
Dr. Francisco Hernandez Munoz, M.d, M.D
Infectious Disease — Payments: $4,252
Infectious Disease $4,252
Dr. Andrew Chao, M.d, M.D
Infectious Disease — Payments: $4,005
Infectious Disease $4,005
Dr. Kepler Davis, M.d, M.D
Infectious Disease — Payments: $3,326
Infectious Disease $3,326
Jacobo Leon, Md, MD
Infectious Disease — Payments: $1,182
Infectious Disease $1,182